These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35345673)

  • 1. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
    Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
    Front Immunol; 2022; 13():857308. PubMed ID: 35345673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms.
    Liu JQ; Liao XW; Wang XK; Yang CK; Zhou X; Liu ZQ; Han QF; Fu TH; Zhu GZ; Han CY; Su H; Huang JL; Ruan GT; Yan L; Ye XP; Peng T
    BMC Gastroenterol; 2020 Dec; 20(1):415. PubMed ID: 33302876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis suggests that LY6H is a potential biomarker of diagnosis, immunoinfiltration, and prognosis.
    Qin H; Lu H; Qin C; Huang X; Peng K; Li Y; Lan C; Bi A; Huang Z; Wei Y; Liao X; Peng T; Zhu G
    J Cancer; 2024; 15(17):5515-5539. PubMed ID: 39308669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic pan-cancer analysis insights into ICAM1 as an immunological and prognostic biomarker.
    Yang C; Ni B; Shen L; Li Z; Zhou L; Wu H; Zhang Y; Liu L; Liu J; Tian L; Yan L; Jin X
    FASEB J; 2024 Jul; 38(13):e23802. PubMed ID: 38979944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPC2 as a diagnostic and prognostic marker regulated progression of colorectal cancer.
    Wang R; Lin X
    Arab J Gastroenterol; 2024 Feb; 25(1):51-57. PubMed ID: 38220478
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Zhang H; Liu J
    Transl Cancer Res; 2024 Feb; 13(2):1026-1042. PubMed ID: 38482423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of the oncogenic and immunological role of SPON2 in human tumors.
    Tang J; Huang Q; Li X; Gu S
    Medicine (Baltimore); 2023 Sep; 102(37):e35122. PubMed ID: 37713832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
    Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
    Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
    Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 19. UBR1 is a prognostic biomarker and therapeutic target associated with immune cell infiltration in gastric cancer.
    Yuan W; Han J; Chen C; Qiu Y; Xu Y; Huang Y; Chen Z; Xu A; Sun M
    Aging (Albany NY); 2024 Aug; 16(16):12029-12049. PubMed ID: 39181686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.
    Li Y; Fei H; Xiao Z; Lu X; Zhang H; Liu M
    Clin Exp Pharmacol Physiol; 2024 Aug; 51(8):e13902. PubMed ID: 38886133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.